"We are very pleased to have completed the negotiation for these monies and are working diligently to maximize other non-dilutive capital inflows including insurance recoveries," said Dr James Campbell, Chief Executive Officer and Managing Director of Patrys. "These funds will be used to fund company operations, including the development of the PAB-DX1 program through pre-clinical studies as we progress what we believe to be an increasingly exciting early stage asset."
-Ends- For further information, please contact:Patrys Limited: | Patrys IR: | Patrys Media: |
James Campbell | Kyahn Williamson | Kellie Stanborough |
Chief Executive Officer | Buchan Consulting | Buchan Consulting |
P: +61 3 96703273 | P: +61 3 9866 4722 | P: +61 3 9866 4722 |
info@patrys.com | kwilliamson@buchanwe.com.au | kstanborough@buchanwe.com.au |
Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at www.patrys.com.
1
Patrys Limited published this content on 01 May 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 03 May 2017 01:08:15 UTC.
Original documenthttp://www.patrys.com/site/market-announcements/2017/464 Finance Update_1 May 2017.pdf
Public permalinkhttp://www.publicnow.com/view/207F45B5CC7A824A13FBA55989B0844A257D1B15